Rezolute's pipeline is anchored by two main programs: ersodetug for hyperinsulinism and RZ402 for DME. Ersodetug is currently in Phase 3 trials for both congenital hyperinsulinism (CHI ...

If so, does this give clues to separating chaperoning from inhibitory effects? The authors suggest that the novel compound may be a promising therapeutic for the treatment of congenital ...

The Food and Drug Administration (FDA) has granted Orphan Drug designation to ersodetug (RZ358) for the treatment of hypoglycemia due to tumor hyperinsulinism (HI). Tumor HI is a rare condition that ...

Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, ...

This would be regarding the use of ersodetug in the ongoing phase 3 sunRIZE study targeting patients with Congenital Hyperinsulinism [cHI]. The reason investors should care about this trial before ...

These forward-looking statements include but are not limited to statements regarding the ersodetug Expanded Access Program, the ability of ersodetug to become an effective treatment for congenital ...

(Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, today announced the U.

About Tumor Hyperinsulinism (HI ... benefit in clinical trials and real-world use for the treatment of congenital HI and tumor HI. For more information, visit www.rezolutebio.com.